The vehicle would put private biotech positions and royalty interests into a quarterly-tender wrapper, but only for investors who clear the qualified client bar.

July 30, 2026

RTW Investments, the New York healthcare specialist that managed roughly $9.7 billion as of June 30, has registered a perpetual non-traded closed-end fund that would carry its biotechnology strategy into advisor-sold channels. RTW Biotech Growth Fund, a Delaware statutory trust formed on June 30, 2026, would pursue long-term capital appreciation across public equities, privately held companies and royalty interests in the life sciences, with shareholder liquidity confined to periodic tender offers.

The fund is registered as a non-diversified, closed-end management investment company, and it is not an interval fund. Repurchases would run as discretionary tender offers under Rule 13e-4 rather than the standing mechanism of Rule 23c-3, subject in each case to board approval. The adviser intends to recommend quarterly offers for up to 5% of shares outstanding under normal conditions, beginning no later than twelve months after the fund commences investment operations. Shareholders would have no redemption right, shares are not expected to be listed, and an early repurchase fee would apply to shares held less than a year, at a rate left blank in the document.

A single-sector mandate spanning the full life cycle

Under normal circumstances the fund would hold at least 80% of net assets, plus borrowings for investment purposes, in biotechnology and biotechnology-related growth companies, a category the adviser defines broadly enough to take in life sciences, biopharmaceuticals, medical technology, diagnostics, genetic medicine and life sciences tools. A fundamental policy commits more than 25% of total assets to those industries.

Within that, the fund would generally target 50% to 100% in public investments, up to 40% in private assets and up to 10% in royalties, revenue interests and milestone payments. The book would be global with a primary focus on the United States, Asia and Europe, and would span the full corporate life cycle, including early-stage private financings and companies formed or supported in connection with the adviser’s own research activity.

Appreciation rather than income

The stated objective is capital appreciation rather than income. Distributions would be made annually, in amounts the fund describes as uncertain, sized to the regulated investment company requirement to distribute at least 90% of taxable income, and the prospectus warns that distributions may come in significant part from asset sales, borrowings, return of capital, offering proceeds or adviser expense support subject to later recoupment. Shares would be sold only to qualified clients as defined under the Advisers Act, a higher wealth bar than accredited-investor eligibility, and the fund would charge an incentive fee.

Three classes are contemplated, designated S, D and I, but the multi-class structure depends on an exemptive order the fund has yet to seek. Until relief is granted, Class I would be the only class available for purchase. Stated minimums, all bracketed as placeholders, are $50,000 for Class S and Class D and $1 million for Class I, with additional investments of $5,000 and $250,000 respectively, and discretion to aggregate intermediary client accounts or waive minimums outright. Subscriptions would be accepted on the first business day of each month at the prior month-end net asset value, plus any sales load, with subscription documents due five business days ahead of the acceptance date.

Economics still to be set

Every economic term of consequence remains a placeholder. The management fee would accrue monthly in arrears on managed assets, a base that includes assets attributable to borrowings, at a rate not yet stated. The incentive fee would be charged on total return, measured on a calendar-year basis and paid annually, subject to an annual hurdle, a catch-up, a high water mark and a loss carryforward provision, with none of the percentages filled in. Also unstated:

• Sales charges — the loads on Class S and Class D, and the distribution and servicing fee
• Liquidity costs — the early repurchase fee applicable inside the first year
• Pricing — the initial offering price per share
• Expense support — the terms of an expense limitation and recoupment arrangement, and the length of a voluntary management fee waiver the adviser has agreed to at launch
• Service providers — distributor, custodian, transfer agent, administrator, dividend paying agent and independent accountant, along with the fiscal and taxable year ends

Leverage, valuation and the affiliate question

Borrowing capacity follows the standard registered-fund limits, with asset coverage of at least 300% required for debt and 200% for preferred stock. The fund intends to establish a credit line, and identifies funding tender requests and meeting capital calls from portfolio investments among its intended uses, alongside bridging the timing gap between inflows and deployment. The adviser also notes it may sell assets to meet net outflows through tender offers. Proceeds are expected to be invested within three months of receipt, extendable by another three, with private assets explicitly expected to take longer.

Valuation of the private and royalty sleeves would fall to the adviser as the board’s valuation designee, with third-party pricing and valuation services intended for certain positions. That arrangement is standard for the format, though it carries more weight in a portfolio that may hold up to half its assets in instruments without readily available quotations, including pre-IPO financings, PIPEs, structured investments and special purpose vehicles.

The overlap question is addressed directly. RTW already advises a range of pooled vehicles in the same sectors, and the fund intends to seek an exemptive order permitting it to co-invest with affiliated accounts in privately negotiated transactions. The document acknowledges that the conditions attached to such an order may limit the fund’s participation, and that without it the Investment Company Act’s affiliate restrictions would bind the registered fund while leaving RTW’s unregistered funds free to transact.

Governance still being assembled

The board is described as comprising four trustees with an independent majority, in brackets; the registration statement itself was executed by Darshan Patel as sole trustee. Roderick Wong, RTW’s founder, managing partner and chief investment officer, signed as chief executive officer, with Robert Aurigema as chief financial officer. Wong and Naveen Yalamanchi, a partner at the firm, are named as the portfolio managers. RTW’s team numbers 94 professionals, headquartered in New York with offices in London, Shanghai, Singapore and Abu Dhabi. Kirkland & Ellis is counsel to the fund.

Because the submission carries a delaying amendment, the offering cannot begin until the registration statement is declared effective, and the document contains no aggregate offering amount; the filing fee table was submitted as a separate exhibit. The fund has no operating history, and the pricing, distribution partner and service provider lineup that will determine how this reaches advisor platforms are all still to come.